No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
Heron Therapeutics Price Target Maintained With a $4.00/Share by Needham
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Recent 16% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
Heron Therapeutics, Inc. (NASDAQ:HRTX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected To Breakeven In The Medium-Term
Is Heron Therapeutics (HRTX) a Good Investment Now?